title: The prognostic value of peripheral blood lymphocyte subsets in patients with bladder carcinoma treated using neoadjuvant M-VEC chemotherapy.
abstract: OBJECTIVE
  To assess the prognostic value of peripheral blood lymphocyte subsets in patients with bladder cancer who were treated with neoadjuvant chemotherapy.
  
  
  METHODS
  Thirty patients with a histological diagnosis of invasive bladder transitional cell carcinoma and 30 age-matched controls with no evidence of cancer and immunological disorders were evaluated. Peripheral blood samples were assessed in both groups using monoclonal antibodies. Patients with bladder cancer who achieved complete or partial responses and those who had progression of the disease after systemic chemotherapy with methotrexate, vinblastine, epirubicin and cisplatin were compared according to the pretreatment values of the peripheral blood lymphocyte subsets.
  
  
  RESULTS
  There were no significant differences in B lymphocyte levels between the groups. In patients with bladder cancer, the percentages of T lymphocytes (P<0.01), natural killer (NK) cells (P<0.05) and the CD4+/CD8+ ratio (P<0.05) were significantly lower than in the control group. In patients who responded to the chemotherapy regimen, the pretreatment values of T lymphocytes (P<0.001), the CD4+/CD8+ ratio (P<0.01) and NK cell levels (P<0.01) were significantly higher than in the patients who did not.
  
  
  CONCLUSIONS
  In patients with invasive bladder carcinoma, cell-mediated immunity may have a role in the resistance to this malignancy and in these patients the pretreatment levels of T lymphocyte subsets may be an indicator of the potential response to chemotherapy.
authors.affiliation: Department of Urology, University of Ankara, Turkey.
authors.forename: T
authors.initials: T
authors.lastname: Soygür
authors.forename: Y
authors.initials: Y
authors.lastname: Bedük
authors.forename: S
authors.initials: S
authors.lastname: Baltaci
authors.forename: O
authors.initials: O
authors.lastname: Yaman
authors.forename: G
authors.initials: G
authors.lastname: Tokgöz
mesh_terms: D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D016131:Lymphocyte Subsets; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D015703:Antigens, CD; D015251:Epirubicin; D014747:Vinblastine; D002945:Cisplatin; D008727:Methotrexate